Literature DB >> 31030823

Benign Prostatic Hyperplasia.

Robert C Langan1.   

Abstract

Benign prostatic hyperplasia (BPH) is a common condition in aging men that is frequently associated with troublesome lower urinary tract symptoms (LUTS). The American Urologic Association Symptom Index is a validated, self-administered tool that is used to diagnose LUTS, guide initial treatment, and assess treatment response. Watchful waiting is an option for men with mild symptoms. Pharmacologic treatment includes alpha-adrenergic blockers and 5-alpha reductase inhibitors. There is no evidence to support the use of herbal supplements in the treatment of LUTS. Surgical therapy is effective and indicated for men with complications from BPH or who fail medical therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  5-alpha reductase inhibitors; Alpha-adrenergic blockers; Benign prostatic hyperplasia; Lower urinary tract symptoms; Transurethral resection of the prostate

Mesh:

Substances:

Year:  2019        PMID: 31030823     DOI: 10.1016/j.pop.2019.02.003

Source DB:  PubMed          Journal:  Prim Care        ISSN: 0095-4543            Impact factor:   2.907


  29 in total

1.  Urinary and sexual function changes in benign prostatic hyperplasia patients before and after transurethral columnar balloon dilatation of the prostate.

Authors:  Dong-Peng Zhang; Zheng-Bo Pan; Hai-Tao Zhang
Journal:  World J Clin Cases       Date:  2022-07-16       Impact factor: 1.534

2.  Efficacy and Safety of Transurethral Columnar Balloon Dilation of the Prostate for the Treatment of Benign Prostatic Hyperplasia: A Multicenter Trial.

Authors:  Guoyun Zhou; Jinkui He; Guangyi Huang; Ligang Ren; Wensong Zhuge; Wei Wang
Journal:  Comput Math Methods Med       Date:  2022-06-09       Impact factor: 2.809

3.  Evaluation of the clinical pharmacist role in improving clinical outcomes in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Mera Ababneh; Duaa Shamieh; Saddam Al Demour; Abeer Rababa'h
Journal:  Int J Clin Pharm       Date:  2019-09-06

4.  Urosepsis and the urologist!

Authors:  James Ryan; Eoghan O'Neill; Liza McLornan
Journal:  Curr Urol       Date:  2021-03-29

5.  The effectiveness of electrical stimulation for the management of benign prostatic hyperplasia: A protocol for systematic review and meta analysis.

Authors:  Wei-Jun Han; Yu-Ge Guo; Yun-Qi Wang; Jin-Wan Wang
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.889

Review 6.  Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia.

Authors:  Zhao-Jun Yu; Hai-Lan Yan; Fang-Hua Xu; Hai-Chao Chao; Lei-Hong Deng; Xiang-Da Xu; Jian-Biao Huang; Tao Zeng
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

7.  The association between metabolic syndrome and lower urinary tract symptoms suggestive of benign prostatic hyperplasia in aging males: evidence based on propensity score matching.

Authors:  Yang Xiong; Yangchang Zhang; Jun Tan; Feng Qin; Jiuhong Yuan
Journal:  Transl Androl Urol       Date:  2021-01

8.  Loss of vision after transurethral resection of prostate: A case report.

Authors:  Sepideh Emami; Fatima Alfaham; Behnam Shakiba; Mehran Moghimian; Zahra Mirzaasgari
Journal:  Urol Case Rep       Date:  2021-06-02

9.  Prevalence, risk factors and quality of life of Lower Urinary Tract Symptoms (LUTS) among men attending Primary Care slum clinics in Bangalore: A cross-sectional study.

Authors:  Priyesh Kant; Leeberk Raja Inbaraj; Nirupama Navamani Franklyn; Gift Norman
Journal:  J Family Med Prim Care       Date:  2021-07-02

10.  Incaspitolide A extracted from Carpesium cernuum induces apoptosis in vitro via the PI3K/AKT pathway in benign prostatic hyperplasia.

Authors:  Xiaoyue Chen; Jingrui Song; Dongbo Yuan; Qing Rao; Kehua Jiang; Shuhui Feng; Guohua Zhu; Chen Yan; Yanmei Li; Jianguo Zhu
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.